At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Aug 11, 2026 at 08:00 ET
Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07 per share) vs $13.1M ($1.93 per share) in Q2 2025, driven by a $9.2M decrease in contingent consideration fair value adjustment. The company dosed first patients in the VIRAGE2 Phase 2a trial evaluating more frequent VCN-01 dosing in metastatic PDAC, but cash runway extends only into Q1 2027 with $11.3M on hand, raising financing risk for a clinical-stage company with no revenue.
- First patients dosed in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment expected to complete H2 2026 with data by Q3 2027
- Cash and cash equivalents of $11.3M as of June 30, 2026; cash runway into Q1 2027
- Net loss of $3.2M for Q2 2026 vs $13.1M in Q2 2025, primarily due to a $9.2M decrease in contingent consideration fair value adjustment
- General and administrative expenses decreased 82% to $2.0M from $11.2M; R&D expenses decreased 35% to $1.3M from $2.0M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access